A method to quantitate the neutralizing capacity of anti-therapeutic protein antibodies in serum and their correlation to clinical impact

Journal of Pharmaceutical and Biomedical Analysis

Volumn 102, Issue , 2014, Pages 176-183

  Kaliyaperumal, Arunan ^a   Pennucci, Jason ^a   Nagatani, Janice ^a   Juan, Gloria ^a   Swanson, Steven ^a   Gupta, Shalini ^a  

^a AMGEN INC   (United States)

Author keywords

Immunogenicity; Neutralizing antibodies; Neutralizing capacity; Quantitation; Therapeutic proteins

Indexed keywords

NEUTRALIZING ANTIBODY; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG PURIFICATION; DRUG RESPONSE; DRUG SCREENING; EC50; FEMALE; HUMAN; MALE; METHODOLOGY; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ANIMAL; CELL CULTURE; IMMUNOLOGY; RABBIT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; HUMANS; RABBITS;

EID: 84907681721     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.09.009     Document Type: Article

References (21)

1. Porter S. Human immune response to recombinant human proteins. J. Pharm. Sci. 2001, 90:1-11.
2. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469-475.
3. Schellekens H., Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 2004, 251(Suppl. 2):II4-II9.
4. de Vries M.K., Wolbink G.J., Stapel S.O., de Vrieze H., van Denderen J.C., Dijkmans B.A., Aarden L.A., van der Horst-Bruinsma I.E. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 2007, 66:1252-1254.
5. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
6. Van Schouwenburg P.A., Krieckaert C.L., Nurmohamed M., Hart M., Rispens T., Aarden L., Wouters D., Wolbink G.J. IgG4 production against adalimumab during long term treatment of RA patients. J. Clin. Immunol. 2012, 32:1000-1006.
7. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1-18.
8. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1-9.
9. Koren E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 2002, 3:349-360.
10. EMEA Guideline on immunogenicity assessment of biotechnology derived therapeutic protein, 2007.
11. Kaliyaperumal A., Chauhan V.S., Talwar G.P., Raghupathy R. Carrier-induced epitope-specific regulation and its bypass in a protein-protein conjugate. Eur. J. Immunol. 1995, 25:3375-3380.
12. Putz M.M., Midgley C.M., Law M., Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccina virus provides a benchmark for smallpox vaccination. Nat. Med. 2006, 12:1310-1315.
13. Grossberg S.E., Kawade Y., Kohase M., Yokoyama H., Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon. Cytokine Res. 2001, 21:729-742.
14. Grossberg S.E., Kawade Y., Kohase M., Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon. Cytokine Res. 2001, 21:743-755.
15. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J. Interferon. Res. 1980, 1:61-70.
16. Kawade Y., Watanabe Y. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer. J. Interferon. Res. 1984, 4:571-584.
17. Kelley M., Cooper C., Matticoli A., Greway A. The detection of anti-erythropoietin antibodies in human serum and plasma: part II. Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies. J. Immunol. Methods 2005, 300:179-191.
18. Kawade Y., Finter N., Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 2003, 278:127-144.
19. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 2003, 278:1-17.
20. Wadhwa M., Gaines-Das R., Thorpe R., Mire-Sluis A. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. Dev. Biol. (Basel) 2005, 122:155-170.
21. Wadhwa M., Bird C., Fagerberg J., Gaines-Das R., Ragnhammar P., Mellstedt H., Thrope R. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 1996, 104:351-358.